GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Spire Healthcare Group PLC (LSE:SPI) » Definitions » Valuation Rank

Spire Healthcare Group (LSE:SPI) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is Spire Healthcare Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Spire Healthcare Group Valuation Rank Related Terms

Thank you for viewing the detailed overview of Spire Healthcare Group's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Spire Healthcare Group (LSE:SPI) Business Description

Traded in Other Exchanges
Address
3 Dorset Rise, London, GBR, EC4Y 8EN
Spire Healthcare Group PLC is an independent hospital group in the United Kingdom, with 40 private hospitals and eight clinics. It is a private provider, by volume, of knee and hip operations in the United Kingdom. The Group is a well-located and scalable hospital have delivered successful and award-winning clinical outcomes, positioning the Group well with patients, Consultants, the NHS, GPs and Private Medical Insurance providers. It treats patients through a variety of routes including PMI, Self-pay and the NHS, providing the Group with diversified access to the expected growth opportunities in the UK healthcare market, which faces significant supply challenges as a result of NHS budget constraints and increasing demand from a growing population with longer life expectancy.